BioNTech (NASDAQ:BNTX) Stock Price Target Lowered at Wells Fargo & Company

BioNTech (NASDAQ:BNTX) had its price target reduced by Wells Fargo & Company from $140.00 to $125.00 in a research report sent to investors on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

BNTX has been the subject of a number of other research reports. Citigroup lowered their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. BMO Capital Markets lowered BioNTech from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. Canaccord Genuity Group decreased their price target on BioNTech from $136.00 to $132.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. Berenberg Bank set a $140.00 price objective on BioNTech in a research report on Wednesday, September 16th. Finally, Bank of America reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $123.60.

BioNTech Stock Performance

NASDAQ BNTX opened at $90.70 on Wednesday. The company has a 50-day simple moving average of $95.68 and a two-hundred day simple moving average of $96.91. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The firm has a market cap of $22.94 billion, a price-to-earnings ratio of -13.24 and a beta of 1.28.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 61.39% and a negative return on equity of 4.45%. The firm’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period last year, the business posted ($1.60) earnings per share. On average, equities analysts forecast that BioNTech will post -6.62 EPS for the current year.

Insider Buying and Selling

In related news, CEO Ugur Sahin sold 36,209 shares of the firm’s stock in a transaction on Friday, October 9th. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33. Following the completion of the sale, the chief executive officer owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock valued at $79,246,837 over the last ninety days. Company insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Flossbach Von Storch SE purchased a new stake in shares of BioNTech in the 2nd quarter worth about $207,142,000. Bank of America Corp DE boosted its stake in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after purchasing an additional 166,432 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of BioNTech by 79.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after purchasing an additional 337,412 shares in the last quarter. First Trust Advisors LP increased its position in shares of BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after buying an additional 451,124 shares during the period. Finally, Candriam S.C.A. increased its position in shares of BioNTech by 4.7% during the third quarter. Candriam S.C.A. now owns 520,972 shares of the company’s stock valued at $51,399,000 after buying an additional 23,442 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q3 results topped expectations: BioNTech reported EPS of $1.99 versus the $0.76 consensus and revenue of €1.29 billion (about $1.49 billion), ahead of estimates. The company also raised its 2026 revenue guidance midpoint, projecting €1.7–€1.9 billion for the year. Article: BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
• Positive Sentiment: Oncology progress offered potential catalysts: The company highlighted data for pumitamig combinations and reported that gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer. An interim gotistobart analysis is expected before year-end. Article: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Analysts trimmed targets but kept favorable ratings: UBS cut its target to $125 from $135, Morgan Stanley to $106 from $114, and Wells Fargo to $125 from $140. All maintained Buy or Overweight ratings, suggesting they still see upside from the recent share price. UBS Group recommendations
• Negative Sentiment: Revenue and pipeline risks remain: Q3 revenue fell 15.1% year over year amid lower COVID-19 vaccine demand. A bearish analysis also flagged ongoing cash burn, declining liquid assets and reliance on a narrower oncology pipeline centered on pumitamig and gotistobart. Article: BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.